PlainRecalls
FDA Drug Moderate Class II Ongoing

Ranitidine Syrup (Ranitidine Oral Solution, USP), 15 mg/mL (75 mg/5mL) 474 mL bottle, Rx only Distributed by: Aurobindo Pharma USA Inc. 279 Princeton-Hightstown Road East Windsor, NJ 08520 Made in India NDC 65862-431-74

Reported: December 4, 2019 Initiated: November 6, 2019 #D-0529-2020

Product Description

Ranitidine Syrup (Ranitidine Oral Solution, USP), 15 mg/mL (75 mg/5mL) 474 mL bottle, Rx only Distributed by: Aurobindo Pharma USA Inc. 279 Princeton-Hightstown Road East Windsor, NJ 08520 Made in India NDC 65862-431-74

Reason for Recall

CGMP Deviations: N-nitrosodimethylamine (NDMA) has been detected in Ranitidine tablets, capsules and syrups.

Details

Recalling Firm
AuroMedics Pharma LLC
Units Affected
19320 bottles
Distribution
nationwide
Location
East Windsor, NJ

Frequently Asked Questions

What product was recalled?
Ranitidine Syrup (Ranitidine Oral Solution, USP), 15 mg/mL (75 mg/5mL) 474 mL bottle, Rx only Distributed by: Aurobindo Pharma USA Inc. 279 Princeton-Hightstown Road East Windsor, NJ 08520 Made in India NDC 65862-431-74. Recalled by AuroMedics Pharma LLC. Units affected: 19320 bottles.
Why was this product recalled?
CGMP Deviations: N-nitrosodimethylamine (NDMA) has been detected in Ranitidine tablets, capsules and syrups.
Which agency issued this recall?
This recall was issued by the FDA Drug on December 4, 2019. Severity: Moderate. Recall number: D-0529-2020.